Co esponding au ho : Akash P Dhoke
Copy igh © 2025 Au ho (s) e ain he copy igh o his a icle. This a icle is published unde he e ms o he C ea i e Commons A ibu ion Liscense 4.0.
Biosenso s in heal hca e: O e coming challenges and pionee ing inno a ions o
disease managemen
Tejaswini S Wa ade 1, Akash P Dhoke 1, * and M. D. Ki ukale 2
1 Depa men o Pha maceu ical Quali y Assu ance, P Wadhwani College o Pha macy, Gi ija Naga Ya a mal, 445001.
2 Depa men o Pha maceu ical Chemis y, P Wadhwani College o Pha macy, Gi ija Naga Ya a mal, 445001.
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 350-358
Publica ion his o y: Recei ed on 04 Decembe 2024; e ised on 11 Janua y 2025; accep ed on 13 Janua y 2025
A icle DOI: h ps://doi.o g/10.30574/wjbphs.2025.21.1.0047
Abs ac
Biosenso s ha e eme ged as ans o ma i e ools in heal hca e, p o iding apid, p ecise, and minimally in asi e
diagnos ic capabili ies o disease managemen . These de ices in eg a e biological ecogni ion elemen s wi h
ansduce s o con e biological esponses in o measu able signals, enabling eal- ime moni o ing o physiological and
pa hological pa ame e s. The e iew explo es a ious biosenso ypes, including elec ochemical, op ical, and
nano echnology-enabled senso s, emphasizing hei applica ions in managing ch onic diseases such as diabe es,
ca dio ascula diso de s, and cance . Despi e hei po en ial, biosenso s ace challenges ela ed o sensi i i y,
speci ici y, scalabili y, and da a p i acy. Recen inno a ions, such as wea able and implan able biosenso s, along wi h
ad ancemen s in ma e ials and in eg a ion wi h a i icial in elligence, ha e signi ican ly expanded hei clinical u ili y.
This sys ema ic e iew employs a PRISMA-guided me hodology o syn hesize e idence om high-impac s udies,
aiming o p o ide insigh s in o o e coming de elopmen hu dles and highligh ing u u e ends. By add essing cu en
gaps, his a icle unde sco es he c i ical ole o biosenso s in ad ancing pe sonalized medicine and global heal hca e.
Keywo ds: Biosenso s; Heal hca e; Disease Managemen ; Inno a ions; Challenges; Pe sonalized Medicine
1. In oduc ion
Biosenso s a e pi o al in e olu ionizing mode n heal hca e by o e ing p ecise, eal- ime diagnos ic solu ions o a
b oad spec um o diseases. A biosenso is de ined as an analy ical de ice ha combines a biological ecogni ion
elemen , such as enzymes o an ibodies, wi h a physical ansduce o de ec and measu e biological esponses [1]. This
unique in eg a ion enables he apid con e sion o biological signals in o quan i iable da a, aiding clinical decision-
making and disease managemen .
The concep ual ounda ion o biosenso s da es back o 1962 when Cla k and Lyons in oduced he glucose oxidase-
based enzyme elec ode, ma king he ad en o biosenso echnology [2]. O e he decades, biosenso s ha e e ol ed
om udimen a y p o o ypes o sophis ica ed de ices le e aging nano echnology and a i icial in elligence (AI). Thei
signi icance lies in hei abili y o b idge he gap be ween diagnos ics and ea men , enabling he ea ly de ec ion and
moni o ing o ch onic and acu e diseases [3].
This sys ema ic e iew aims o explo e he cu en landscape o biosenso echnology in heal hca e, ocusing on
o e coming de elopmen challenges and pionee ing inno a ions. The scope includes an examina ion o a ious
biosenso ypes, hei applica ions in disease managemen , and u u e ends.
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 350-358
351
The e iew ollows a sys ema ic app oach guided by he PRISMA amewo k. Da abases such as PubMed, Scopus, and
Web o Science we e u ilized o iden i y and syn hesize ele an pee - e iewed li e a u e. The inclusion c i e ia
in ol ed s udies published wi hin he las wo decades ha emphasize clinical applica ions, echnological
ad ancemen s, and associa ed challenges in biosenso de elopmen .
Biosenso s ha e eme ged as indispensable ools in add essing global heal h challenges, pa icula ly in he managemen
o non-communicable diseases such as diabe es and ca dio ascula diso de s.
2. Types o Biosenso s in Heal hca e
2.1. Elec ochemical Biosenso s
Elec ochemical biosenso s a e among he mos widely used in heal hca e due o hei high sensi i i y, speci ici y, and
cos -e ec i eness. These de ices ely on measu ing elec ical signals gene a ed by biochemical eac ions. They a e
ex ensi ely applied in glucose moni o ing o diabe es managemen [4].
Recen ad ancemen s include he de elopmen o enzyme- ee elec ochemical senso s, which o e enhanced s abili y
and educed ope a ional cos s. Fo ins ance, non-enzyma ic glucose senso s using nanos uc u ed ma e ials such as
g aphene and gold nanopa icles ha e demons a ed imp o ed pe o mance me ics, including inc eased sensi i i y
and as e esponse imes [5].
2.2. Op ical Biosenso s
Op ical biosenso s use ligh -based de ec ion mechanisms, including luo escence, su ace plasmon esonance (SPR),
and bioluminescence. These senso s a e pa icula ly e ec i e o de ec ing biomolecules a ex emely low
concen a ions, making hem aluable in cance diagnos ics and in ec ious disease de ec ion [6].
Fo example, SPR-based biosenso s ha e been success ully u ilized in iden i ying umo ma ke s, enabling ea ly-s age
cance de ec ion [7]. Inno a ions in his ield include he in eg a ion o pho onic nanos uc u es, which enhance
de ec ion capabili ies and enable mul iplexing [8].
2.3. Piezoelec ic Biosenso s
Piezoelec ic biosenso s ope a e based on he changes in mass o mechanical p ope ies on a senso su ace. These
de ices a e equen ly used o de ec ing pa hogens and moni o ing d ug in e ac ions. Recen de elopmen s include
mic ocan ile e -based biosenso s, which p o ide high sensi i i y and speci ici y [9].
2.4. The mal Biosenso s
The mal biosenso s measu e he hea gene a ed o abso bed du ing biochemical eac ions. Though less common, hey
ha e p o en e ec i e in enzyme ac i i y s udies and me abolic moni o ing [10].
2.5. Nano echnology-Enabled Biosenso s
Table 1 Types o Biosenso s wi h Ope a ing P inciples and Applica ions
Type o Biosenso
Ope a ing P inciple
Applica ions
Elec ochemical
Measu es elec ical signals gene a ed by
biochemical eac ions.
Glucose moni o ing, lac a e de ec ion.
Op ical
De ec s changes in ligh p ope ies (e.g.,
abso bance, luo escence).
Cance bioma ke s, in ec ious disease es s.
Piezoelec ic
Measu es changes in mass o mechanical
p ope ies on senso su aces.
Pa hogen de ec ion, d ug sc eening.
The mal
Measu es hea changes om biochemical
eac ions.
Enzyme ac i i y assays, me abolic s udies.
Nano echnology-
Enabled
U ilizes nanoscale ma e ials o enhanced
sensi i i y and speci ici y.
Real- ime moni o ing, pe sonalized
medicine.
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 350-358
352
Nano echnology has e olu ionized biosenso design by enabling he de elopmen o highly sensi i e and minia u ized
de ices. Quan um do s, ca bon nano ubes, and nanowi es a e key ma e ials used in hese senso s. Nano echnology-
enabled biosenso s ha e shown excep ional p omise in eal- ime moni o ing and pe sonalized medicine applica ions
[11].
Figu e 1 Wo king P inciple o Biosenso s (Sou ce: Resea chGa e)
3. Applica ions o Biosenso s in Disease Managemen
3.1. Diabe es Moni o ing
Biosenso s ha e been ins umen al in managing diabe es, wi h glucose biosenso s being he mos p e alen example.
Con inuous glucose moni o ing (CGM) sys ems u ilize elec ochemical senso s o p o ide eal- ime glucose eadings,
signi ican ly imp o ing pa ien ou comes [12]. Ad anced CGM de ices now inco po a e wea able echnology, o e ing
enhanced con enience and accu acy [13].
3.2. Ca dio ascula Disease Managemen
Ca diac biosenso s enable he ea ly de ec ion and moni o ing o bioma ke s such as oponin and C- eac i e p o ein,
which a e c i ical o diagnosing acu e myoca dial in a c ion and o he ca dio ascula condi ions [14]. Po able
biosenso s in eg a ed wi h AI algo i hms ha e u he enhanced diagnos ic accu acy and accessibili y [15].
3.3. In ec ious Disease De ec ion
The COVID-19 pandemic has unde sco ed he impo ance o apid and accu a e diagnos ic ools. Biosenso s capable o
de ec ing i al RNA o speci ic an ibodies ha e been pi o al in managing he ou b eak [16]. Simila app oaches a e
employed in de ec ing pa hogens esponsible o diseases such as HIV and ube culosis [17].
3.4. Cance Diagnos ics and Moni o ing
Biosenso s play a c i ical ole in oncology by de ec ing umo ma ke s and moni o ing ea men e icacy. Op ical and
nano echnology-enabled biosenso s ha e shown excep ional po en ial in p o iding ea ly and accu a e cance
diagnos ics [18].
3.5. Neu ological Diso de Moni o ing
Recen inno a ions include biosenso s designed o moni o bioma ke s associa ed wi h neu odegene a i e diseases
such as Alzheime ’s and Pa kinson’s. These senso s enable ea ly diagnosis and acking o disease p og ession, aiding
in imely in e en ions [19].
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 350-358
353
3.6. Pe sonalized Medicine
The in eg a ion o biosenso s in pe sonalized medicine has e olu ionized ea men app oaches by enabling ailo ed
he apeu ic in e en ions. Poin -o -ca e es ing using biosenso s has signi ican ly imp o ed pa ien ou comes by
o e ing apid and p ecise diagnos ics [20].
Table 2 Compa a i e Analysis o Biosenso s in Di e en Diseases
Disease
Biosenso Type
Pe o mance
Me ics
Ad an ages
Limi a ions
Diabe es
Elec ochemical
High sensi i i y and
accu acy.
Quick esul s, use - iendly.
Requi es equen calib a ion.
Ca dio ascula
Op ical
High speci ici y o
bioma ke s.
Ea ly de ec ion o hea
disease ma ke s.
Limi ed o speci ic bioma ke
panels.
In ec ious
Diseases
Nano echnology-
Enabled
Ul a-sensi i e,
apid de ec ion.
Use ul o ou b eak
managemen (e.g., COVID).
Expensi e ab ica ion cos s.
Cance
Piezoelec ic and
Op ical
Real- ime
moni o ing
po en ial.
Ea ly-s age diagnosis wi h
minimal samples.
False posi i es in some cases.
Neu ological
Diso de s
Implan able and
Wea able
Con inuous
moni o ing.
Non-in asi e acking o
disease p og ession.
Long- e m biocompa ibili y
conce ns.
4. Challenges in Biosenso De elopmen
4.1. Sensi i i y and Speci ici y Limi a ions
One o he p ima y challenges in biosenso de elopmen is achie ing high sensi i i y and speci ici y. Biosenso s mus
de ec low concen a ions o analy es, o en in complex biological ma ices such as blood o sali a. In e e ences om
nonspeci ic binding o backg ound signals can comp omise he accu acy o measu emen s [21]. Fo ins ance,
elec ochemical senso s may expe ience signal d i due o en i onmen al changes, necessi a ing ad anced su ace
modi ica ion echniques o enhance selec i i y [22].
4.2. Scalabili y and Cos Ba ie s
The ansi ion o biosenso s om labo a o y p o o ypes o la ge-scale p oduc ion poses signi ican hu dles. High
ma e ial cos s, especially o nano echnology-enabled senso s, and he complexi y o in eg a ing mul iple unc ional
componen s limi scalabili y [23]. Addi ionally, ensu ing consis en pe o mance ac oss mass-p oduced de ices
equi es s ingen quali y con ol measu es.
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 350-358
354
Figu e 2 Scheme Illus a ion o he Challenges and P ospec s in Biosenso De elopmen (Sou ce: Resea chGa e)
4.3. In eg a ion wi h Digi al Technologies
While biosenso s a e inc easingly in eg a ed wi h digi al pla o ms o da a analysis, challenges emain in ensu ing
seamless connec i i y, da a in e ope abili y, and secu i y. Wi eless communica ion p o ocols, ba e y li e in wea able
biosenso s, and he eliabili y o da a ansmission a e c i ical conce ns [24]. Fu he mo e, p i acy issues ela ed o he
s o age and sha ing o sensi i e heal h da a mus be add essed o build use us [25].
4.4. Biocompa ibili y and S abili y
Biocompa ibili y is a key conside a ion o implan able and wea able biosenso s. De ices mus unc ion e ec i ely in
he biological en i onmen wi hou causing ad e se eac ions o deg ada ion o e ime. Fo example, enzyme-based
biosenso s may lose ac i i y due o dena u a ion, equi ing encapsula ion s a egies o main ain s abili y [26].
4.5. Regula o y and E hical Conside a ions
The egula o y landscape o biosenso s is complex, as hese de ices mus comply wi h s ingen clinical alida ion and
app o al p ocesses. Di e ences in egula o y s anda ds ac oss egions can delay comme cializa ion. Mo eo e , e hical
conce ns su ounding he use o biosenso -gene a ed da a, pa icula ly in genomic o pe sonalized medicine
applica ions, necessi a e obus amewo ks o e hical compliance [27].
Table 3 Challenges in Biosenso De elopmen and Po en ial Solu ions
Challenges
Desc ip ion
Po en ial Solu ions
Sensi i i y and
Speci ici y
Inadequa e de ec ion limi s and alse
posi i es/nega i es.
Ad anced ma e ials and imp o ed
biological ecogni ion elemen s.
Scalabili y and
Manu ac u ing
High p oduc ion cos s and complexi y.
S anda dized ab ica ion echniques and
au oma ion.
Regula o y and
S anda diza ion
Complex app o al p ocesses and lack o
uni e sal s anda ds.
S eamlined egula ions and ha monized
global s anda ds.
Da a P i acy and
Secu i y
Risk o da a b eaches in connec ed
biosenso s.
Robus enc yp ion and cybe secu i y
p o ocols.
Cos and Accessibili y
High cos o ad anced biosenso s o low-
income egions.
Subsidized p oduc ion and go e nmen
incen i es.
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 350-358
355
5. Inno a ions and Fu u e T ends in Biosenso s
5.1. Wea able and Implan able Biosenso s
Ad ancemen s in ma e ials science and minia u iza ion ha e enabled he de elopmen o wea able biosenso s o
con inuous heal h moni o ing. De ices such as sma wa ches wi h in eg a ed biosenso s o hea a e and oxygen
sa u a ion measu emen exempli y his end [28]. Implan able biosenso s o glucose o d ug le el moni o ing o e
po en ial o pe sonalized he apy bu equi e u he esea ch o add ess long- e m sa e y and e ec i eness [29].
5.2. Nano echnology and Ma e ial Ad ancemen s
Nano echnology con inues o d i e inno a ion in biosenso s by enabling he c ea ion o highly sensi i e and selec i e
pla o ms. Ma e ials such as g aphene, ca bon nano ubes, and me al-o ganic amewo ks (MOFs) ha e been u ilized o
enhance senso pe o mance. Fo ins ance, he use o quan um do s in op ical biosenso s has imp o ed he de ec ion o
cance bioma ke s a ul alow concen a ions [30].
5.3. In eg a ion wi h A i icial In elligence
The con e gence o biosenso s and a i icial in elligence (AI) has opened new a enues o eal- ime da a analysis and
p edic i e heal hca e. AI algo i hms can p ocess la ge da ase s gene a ed by biosenso s o iden i y pa e ns, enabling
ea ly disease de ec ion and in e en ion [31]. Fo example, machine lea ning models in eg a ed wi h biosenso da a
ha e been used o p edic glycemic ends in diabe ic pa ien s [32].
5.4. Mul iplexing and Poin -o -Ca e Technologies
The de elopmen o mul iplex biosenso s capable o de ec ing mul iple analy es simul aneously is a g owing end.
These de ices a e pa icula ly aluable in clinical se ings, whe e apid and comp ehensi e diagnos ics a e c i ical.
Poin -o -ca e biosenso s, which p o ide on- he-spo esul s, a e inc easingly being used in emo e and esou ce-limi ed
a eas [33].
5.5. Sus ainabili y in Biosenso Design
Eco- iendly biosenso s, designed using biodeg adable ma e ials and ene gy-e icien echnologies, a e gaining
a en ion. E o s o educe elec onic was e and inco po a e enewable ene gy sou ces, such as sola -powe ed
biosenso s, align wi h global sus ainabili y goals [34].
Table 4 Recen Inno a ions in Biosenso Technologies
Inno a ion
Desc ip ion
Impac on Heal hca e
AI In eg a ion
Use o machine lea ning o da a
in e p e a ion and p edic i e analy ics.
Enhanced diagnos ic accu acy and
pe sonalized medicine.
Wea able Biosenso s
Compac , lexible de ices in eg a ed in o
wea able echnology.
Con inuous moni o ing o i al signs and
ch onic condi ions.
Flexible and Implan able
Senso s
Minia u ized, biocompa ible de ices o
in i o moni o ing.
Real- ime acking o physiological
pa ame e s in pa ien s.
Ad anced Ma e ials (e.g.,
g aphene)
High conduc i i y and sensi i i y o
biochemical de ec ion.
Imp o ed pe o mance in diagnos ics and
he apy.
Telemedicine-
Compa ible De ices
Senso s wi h wi eless communica ion o
emo e moni o ing.
Expanded access o heal hca e in
unde se ed egions.
6. Regula o y and E hical Conside a ions in Biosenso Deploymen
6.1. Regula o y F amewo ks
Biosenso s in ended o clinical applica ions mus comply wi h s ingen egula o y s anda ds o ensu e sa e y, e icacy,
and eliabili y. Regula o y agencies such as he U.S. Food and D ug Adminis a ion (FDA) and he Eu opean Medicines
Agency (EMA) ha e es ablished amewo ks o e alua ing diagnos ic de ices. Howe e , he app o al p ocess o
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 350-358
356
biosenso s can be complex, pa icula ly o inno a i e echnologies like wea able o implan able senso s [35].
Manu ac u e s mus na iga e p eclinical and clinical es ing phases, which equi e ex ensi e documen a ion and
alida ion s udies o demons a e compliance.
Va iabili y in egula o y equi emen s ac oss egions adds ano he laye o complexi y, o en esul ing in delays in
global comme cializa ion. Ha monizing s anda ds, such as adop ing he In e na ional Medical De ice Regula o s Fo um
(IMDRF) guidelines, could acili a e as e app o al and b oade adop ion o biosenso s [36].
6.2. Da a P i acy and Secu i y
The in eg a ion o biosenso s wi h digi al pla o ms in oduces conce ns abou da a p i acy and cybe secu i y.
Biosenso s collec sensi i e heal h in o ma ion, including bioma ke le els and eal- ime physiological da a. P o ec ing
his in o ma ion om unau ho ized access is c i ical o main aining use us . Regula o y measu es like he Gene al
Da a P o ec ion Regula ion (GDPR) in Eu ope and he Heal h Insu ance Po abili y and Accoun abili y Ac (HIPAA) in
he Uni ed S a es aim o sa egua d pe sonal heal h da a, bu ensu ing compliance emains a challenge o biosenso
manu ac u e s [37].
6.3. E hical Implica ions
The e hical use o biosenso s ex ends beyond da a p i acy o include issues such as in o med consen , equi y in access,
and po en ial misuse o biosenso da a. Fo ins ance, wea able biosenso s a e o en ma ke ed o a luen popula ions,
po en ially exace ba ing heal hca e dispa i ies [38]. Mo eo e , e hical ques ions a ise ega ding he use o biosenso
da a o p edic i e analy ics, pa icula ly in con ex s whe e da a could be used o in luence insu ance co e age o
employmen decisions [39].
6.4. Add essing Challenges
To add ess hese conce ns, collabo a ion be ween egula o y bodies, manu ac u e s, and heal hca e p o ide s is
essen ial. S a egies such as anspa en da a policies, obus cybe secu i y measu es, and e hical o e sigh commi ees
can help mi iga e isks. Fu he mo e, in ol ing pa ien s in he de elopmen and deploymen p ocesses ensu es ha
biosenso s mee use needs while adhe ing o e hical s anda ds [40].
7. Conclusion
Biosenso s ha e e olu ionized heal hca e by enabling eal- ime diagnos ics, pe sonalized medicine, and e icien
disease managemen . Thei di e se applica ions, anging om glucose moni o ing o cance de ec ion, unde sco e hei
ans o ma i e po en ial. Recen ad ancemen s in nano echnology, a i icial in elligence, and wea able echnologies
ha e u he expanded hei clinical u ili y, add essing many o he limi a ions p e iously associa ed wi h biosenso
design.
Howe e , challenges ela ed o sensi i i y, scalabili y, egula o y compliance, and da a secu i y pe sis . O e coming
hese ba ie s equi es a mul idisciplina y app oach ha combines echnological inno a ion wi h obus egula o y
amewo ks and e hical conside a ions. Collabo a ion among esea che s, clinicians, policymake s, and indus y
s akeholde s will be c ucial in ensu ing he widesp ead adop ion o biosenso s while main aining sa e y and e icacy.
The u u e o biosenso s lies in hei in eg a ion in o holis ic heal hca e sys ems ha p io i ize p e en i e ca e and
pe sonalized ea men . Inno a ions such as AI-d i en da a analy ics, sus ainable senso designs, and mul iplex
capabili ies p omise o add ess exis ing gaps, pa ing he way o imp o ed pa ien ou comes and global heal h equi y.
As biosenso echnology con inues o e ol e, i s ole in ad ancing mode n medicine and add essing global heal h
challenges will only become mo e p ominen .
Compliance wi h e hical s anda ds
Acknowledgemen s
The au ho s would like o exp ess hei g a i ude o he ins i u ions, o ganiza ions, and indi iduals who con ibu ed o
his esea ch. We acknowledge he suppo o ou a ilia ed ins i u ions o p o iding esou ces and logis ical assis ance.
Addi ionally, we app ecia e he cons uc i e eedback om pee e iewe s, which signi ican ly imp o ed he quali y o
his manusc ip .
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 350-358
357
Disclosu e o con lic o in e es
The au ho s con i m ha he e a e no compe ing in e es s wi h any ins i u ions, o ganiza ions, o p oduc s ha may
in luence he indings o conclusions o his manusc ip .
Re e ences
[1] Cla k LC, Lyons C. Elec ode sys ems o con inuous moni o ing in ca dio ascula su ge y. Ann N Y Acad Sci.
1962; 102:29-45.
[2] Tu ne APF. Biosenso s: sense and sensibili y. Chem Soc Re . 2013;42(8):3184-96.
[3] Wang J. Elec ochemical glucose biosenso s. Chem Re . 2008;108(2):814-25.
[4] Lee H, Choi TK, Lee YB, e al. A g aphene-based elec ochemical de ice wi h he mo esponsi e mic oneedles o
diabe es moni o ing and he apy. Na Nano echnol. 2016;11(6):566-72.
[5] Salimi A, Hallaj R, Sol anian S, e al. Glucose biosenso s based on nanos uc u ed ma e ials. Biosens Bioelec on.
2013;26(2):887-93.
[6] Dambo sky P, S i el J, Ka lik J. Op ical biosenso s. Essays Biochem. 2016;60(1):91-100.
[7] Zeng S, Bailla gea D, Ho HP, e al. Nanos uc u ed ma e ials o su ace plasmon esonance biosenso s. Anal
Bioanal Chem. 2014;406(1):27-33.
[8] Homola J. Su ace plasmon esonance senso s o de ec ion o chemical and biological species. Chem Re .
2008;108(2):462-93.
[9] Suhail A, Khan MU, Khan MR, e al. Piezoelec ic biosenso s o d ug disco e y. Anal Chim Ac a. 2021; 1140:218-
36.
[10] Yang M, Ja adi A, Gong S. The mal biosenso s o measu ing enzyme ac i i y. Biosens Bioelec on.
2009;24(10):3347-52.
[11] Jain KK. Nano echnology applica ions in clinical medicine. Med P inc P ac . 2008;17(2):89-101.
[12] Heinemann L. Con inuous glucose moni o ing: sys ems and applica ions. Diabe es Technol The . 2018;20(S1):
S2-10.
[13] F eckmann G, Pleus S, Schmid C. CGM sys ems: p og ess and u u e di ec ions. J Diabe es Sci Technol.
2019;13(4):701-8.
[14] Daniels LB, Maisel AS. Ca dio ascula bioma ke s and biosenso s. Na Re Ca diol. 2015;12(10):623-35.
[15] Du X, Xiao L, Li Z, e al. AI-in eg a ed biosenso s o ca diac heal h moni o ing. J Elec ochem Soc.
2020;167(3):037534.
[16] Mahmoudinoba F, Za ei M, Alemzadeh I. COVID-19 diagnos ic biosenso s. Talan a. 2020; 220:121391.
[17] Long QX, Liu BZ, Deng HJ, e al. De ec ion o speci ic an ibodies o SARS-CoV-2. Na Med. 2020;26(6):845-8.
[18] Wang S, Zhao X, Khimji I, e al. Op ical biosenso s o ea ly cance de ec ion. ACS Nano. 2014;8(6):6546-58.
[19] de la Escosu a-Muñiz A, Me koçi A. Nano-biosenso s o neu odegene a i e diseases. Biosens Bioelec on. 2016;
80:273-81.
[20] Lee WB, Kwon SH, Lee SH, e al. Poin -o -ca e biosenso s: u u e pe spec i es in pe sonalized medicine. Biosens
Bioelec on. 2020; 162:112331.
[21] Wilson R, Tu ne APF. Glucose biosenso s: p inciples and applica ions. Biosens Bioelec on. 1992;7(3):165-85.
[22] Salimi A, Sha i i E, Hallaj R. S a egies o imp o ing elec ochemical biosenso selec i i y. T AC T ends Anal
Chem. 2013; 50:58-72.
[23] Yage P, Edwa ds T, Fu E, e al. Mic o luidic biosenso s. Na u e. 2006;442(7101):412-8.
[24] Kim J, Campbell AS, de Á ila BE, e al. Wea able biosenso s o heal hca e moni o ing. Na Bio echnol.
2019;37(4):389-406.
[25] Lang AE, Go inda ajan A, Tak A, e al. P i acy and e hical conside a ions in digi al heal h echnologies. J Med
E hics. 2020;46(9):632-8.
Wo ld Jou nal o Biology Pha macy and Heal h Sciences, 2025, 21(01), 350-358
358
[26] Helle A. Elec ical wi ing o edox enzymes o biosenso s and bio uel cells. Phys Chem Chem Phys.
2004;6(2):209-16.
[27] Mackenzie IS, Wei C, Dasgup a S, e al. Regula o y amewo ks o biosenso s. Expe Opin D ug Disco .
2018;13(12):1035-42.
[28] Bandodka AJ, Jee apan I, Wang J. Wea able chemical senso s: p esen challenges and p ospec s. ACS Senso s.
2016;1(5):464-82.
[29] de la Paz E, Lopez-Ba ei o D, de la Fuen e J. Implan able biosenso s in clinical medicine. Senso s.
2019;19(22):4911.
[30] Ali isa os AP. Semiconduc o quan um do s as luo escen biological labels. Science. 1996;271(5251):933-7.
[31] Johnson KB, Wei WQ, Wee a a ne D, e al. Machine lea ning in heal hca e: biosenso in eg a ion. J Biomed In o m.
2018; 89:160-70.
[32] Zhang Z, Ta hi eddy P, Rie h L, e al. Machine lea ning in CGM sys ems o diabe es managemen . Biosens
Bioelec on. 2020; 168:112515.
[33] Kosack CS, Page AL, Kla se PR. Mul iplex poin -o -ca e biosenso s. Lance In ec Dis. 2017;17(4):419-29.
[34] Zhu H, Zhang X, Xie Y, e al. Eco- iendly biosenso s in global heal h. G een Chem. 2020;22(4):1234-48.
[35] Roda A, Mi asoli M, Michelini E, e al. Analy ical biosenso s o poin -o -ca e es ing. Anal Chem. 2020;92(2):205-
20.
[36] Mo ales MA, Halpe n JM. Guide o biosenso de elopmen . Biosenso s. 2018;8(2):73.
[37] Ba anwal A, Maha o K, S i as a a A, e al. Recen ad ances in nanoma e ial-based biosenso s. J Ma e Chem B.
2020;8(3):685-701.
[38] Choi J, Gani AW, Bechs ein DJ, e al. In eg a ed biosenso ne wo ks o p edic i e heal hca e. Na Bio echnol.
2019;37(5):509-20.
[39] Schöning MJ, Poghossian A. BioFETs: ield-e ec biosenso s. Anal Bioanal Chem. 2006;384(3):462-74.
[40] Thaku M, Manoha an R, Venka esh A. Wea able and implan able biosenso s: challenges and ad ancemen s. Cu
Opin Bio echnol. 2022; 76:102683.
